English
序号 | 年度 | 论文题目 | 第一作者 | 通讯作者 | 发表期刊、卷期号 | 影响因子（2025） |
1 | 2025 | Targeting ATP7A-Dependent Copper Metabolic Homeostasis Induces Cuproptosis and Suppresses the Progression of Mutant KRAS-Driven Lung Cancer. | 赵健、张伟杰、曾园园 | 刘泽毅、黄建安 | Cancer Res. 2025 Oct 15;85(20):3999-4017. | 22.6 |
2 | 2025 | Targeting ZNRF2-mediated SLC3A2 plasma membrane translocation enhances ferroptosis in lung adenocarcinoma. | 张伟杰、李建军、赵健 | 刘泽毅、黄建安 | Oncogene. 2025 Nov;44(45):4339-4351. | 9.1 |
3 | 2025 | N6-methyladenosine Reader IGF2BP2-modified HMMR Promotes Non-small Cell Lung Cancer Metastasis via Interaction with MAP4K4. | 张建生、张梦珠 | 刘泽毅、张秀琴 | Int J Biol Sci. 2025 Jan 21;21(4):1391-1409. | 11.7 |
4 | 2025 | Liensinine overcomes EGFR-TKI resistance in lung adenocarcinoma through DRP1-mediated autophagy. | 陈昱灵、舒陈影、闫兆威 | 刘泽毅、黄建安 | Phytomedicine. 2025 May;140:156593. | 11.3 |
5 | 2025 | Antiemetic drug fosaprepitant exerts anti-tumor effects against NSCLC by targeting FAK to inhibit AKT and JNK/c-Jun pathways. | 王莹、邵宇娜、麻晨康 | 刘泽毅、闫兆威 | Acta Pharmacol Sin. 2026 Feb;47(2):404-418. | 10.4 |
6 | 2025 | MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway. | 张赛群、陈昱灵 | 刘泽毅、黄建安、穆传勇 | J Transl Med. 2025 Jul 25;23(1):831. | 9.7 |
7 | 2025 | Systems Biology-Based Drug Repositioning Identifies Extracellular Matrix Module as a Therapeutic Target in Lung Squamous Cell Carcinoma. | 杨斌 | 胡广、刘泽毅 | J Med Chem. 2025 Nov 13;68(21):22569-22587. | 7.3 |
8 | 2025 | Elesclomol-Induced Copper Influx Attenuates Lung Adenocarcinoma Progression With Involvement of the ER Stress/PCK2 Axis. | 赵健、陈宜利 | 刘泽毅、黄建安 | FASEB J. 2025 Nov 30;39(22):e71250. | 4.3 |
9 | 2025 | Circular RNA-Cacna1d Plays a Critical Role in Sepsis-induced Lung Injury by Sponging microRNA-185-5p. | 王佳佳 | 黄建安、刘泽毅、陈成 | Am J Respir Cell Mol Biol. 2025 Feb;72(2):181-194. | 5.4 |
10 | 2025 | B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer. | 张杨、杨洋、曾园园 | 黄建安、陈成、刘泽毅 | Front Immunol. 2025 May 20;16:1553042. | 7 |
11 | 2025 | Isoliensinine exerts antitumor effects in lung adenocarcinoma by inhibiting APEX1-driven ROS production. | 陈澄、舒陈影、沈旦 | 刘泽毅、黄建安 | Front Pharmacol. 2025 May 27;16:1555802. | 5.4 |
12 | 2025 | Challenges in diagnosis and treatment of long COVID. | 谷雷 | 黄建安、刘泽毅 | Front Med (Lausanne). 2025 Aug 21;12:1641411. | 3.6 |
13 | 2025 | Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect. | 谷雷 | 黄建安、刘泽毅 | J Inflamm Res. 2025 Oct 11;18:14171-14173. | 4.6 |
14 | 2025 | USP5 influences immune infiltration and prognosis in non-small-cell lung cancer. | 徐永红、谢逸菲、赵健 | 刘泽毅、黄建安 | Pathol Res Pract. 2025 Dec;276:156276. | 3.7 |
15 | 2025 | Targeting MET Signalling Activated by CPNE3-RACK1 Interaction Through VWFA Domain to Suppress Lung Cancer Progression. | 蔡馨、赵健、麻晨康 | 刘泽毅、黄建安 | J Cell Mol Med. 2025 Nov;29(21):e70926. | 4.7 |
16 | 2025 | Pathogen-induced mitochondrial dysfunction: mechanistic insights, immune crosstalk, and therapeutic opportunities. | 杨洋 | 黄建安、刘泽毅 | Front Cell Infect Microbiol. 2025 Dec 1;15:1714998. | 5.5 |